Cardiovascular risk profiles: A cross‐sectional study evaluating the generalizability of the glucagon‐like peptide‐1 receptor agonist cardiovascular outcome trials <scp>REWIND</scp> , <scp>LEADER</scp> and <scp>SUSTAIN</scp> ‐6 to the real‐world type 2 diabetes population in the <scp>United Kingdom</scp>

Abstract

REWIND captured a trial population more representative of the real-world T2D population in the United Kingdom than LEADER or SUSTAIN-6 with regard to both CV and combined CV/core eligibility criteria.